Neurotransmitter transporters: molecular function of important drug targets

Trends in Pharmacological Sciences

Volumn 27, Issue 7, 2006, Pages 375-383

  Gether, Ulrik ^a   Andersen, Peter H ^b   Larsson, Orla M ^c   Schousboe, Arne ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b H LUNDBECK A S   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4,4 DIPHENYL 3 BUTENYL)NIPECOTIC ACID; 1 [2 [TRIS(4 METHOXYPHENYL)METHYL]ETHYL] 3 PIPERIDINECARBOXYLIC ACID; 3 (4 FLUOROPHENYL) 3 (4' PHENYLPHEROXY)]PROPYLSARCOSINE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 4 METHYLAMINO 4,5,6,7 TETRAHYDROBENZO[D]ISOXAZOL 3 OL; 4,5,6,7 TETRAHYDROISOXAZOLO[4,5 C]PYRIDIN 3 OL; ALX 1393; ALX 1405; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZATROPINE; BETA LACTAM ANTIBIOTIC; CARRIER PROTEIN; CITALOPRAM; DESIPRAMINE; EF 1502; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; MAZINDOL; MEMBRANE PROTEIN; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NISOXETINE; NNC 052090; NOMIFENSINE; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; ORG 24598; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIAGABINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANOXERINE;

AMYOTROPHIC LATERAL SCLEROSIS; BACTERIUM; CELL MEMBRANE; CRYSTALLIZATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; EXTRACELLULAR SPACE; GLIA CELL; HUMAN; MAMMAL; MENTAL DISEASE; NERVE CELL; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN QUATERNARY STRUCTURE; PROTEIN STRUCTURE; REVIEW; STRUCTURAL HOMOLOGY;

ANIMALS; HUMANS; MODELS, MOLECULAR; NEUROTRANSMITTER TRANSPORT PROTEINS; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, DRUG;

EID: 33745555489     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2006.05.003     Document Type: Review

References (69)

1. Hediger M.A., et al. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins. Introduction. Pflugers Arch. 447 (2004) 465-468
2. Kanai Y., and Hediger M.A. The glutamate/neutral amino acid transporter family SLC1: molecular, physiological and pharmacological aspects. Pflugers Arch. 447 (2004) 469-479
3. Chen N.H., et al. Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6. Pflugers Arch. 447 (2004) 519-531
4. Goldberg N.R., et al. Probing conformational changes in neurotransmitter transporters: a structural context. Eur. J. Pharmacol. 479 (2003) 3-12
5. Chen N., and Reith M.E. Structure and function of the dopamine transporter. Eur. J. Pharmacol. 405 (2000) 329-339
6. 2+-site engineering. Eur. J. Pharmacol. 479 (2003) 187-197
7. Kanner B.I., and Borre L. The dual-function glutamate transporters: structure and molecular characterisation of the substrate-binding sites. Biochim. Biophys. Acta 1555 (2002) 92-95
8. Torres G.E., et al. Plasma membrane monoamine transporters: structure, regulation and function. Nat. Rev. Neurosci. 4 (2003) 13-25
9. Yernool D., et al. Structure of a glutamate transporter homologue from Pyrococcus horikoshii. Nature 431 (2004) 811-818
10. Haugeto O., et al. Brain glutamate transporter proteins form homomultimers. J. Biol. Chem. 271 (1996) 27715-27722
11. Eskandari S., et al. Pentameric assembly of a neuronal glutamate transporter. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 8641-8646
12. Brocke L., et al. Proximity of two oppositely oriented reentrant loops in the glutamate transporter GLT-1 identified by paired cysteine mutagenesis. J. Biol. Chem. 277 (2002) 3985-3992
13. Seal R.P., et al. A model for the topology of excitatory amino acid transporters determined by the extracellular accessibility of substituted cysteines. Neuron 25 (2000) 695-706
14. -dependent neurotransmitter transporters. Nature 437 (2005) 215-223
15. Huang Y., et al. Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli. Science 301 (2003) 616-620
16. Abramson J., et al. Structure and mechanism of the lactose permease of Escherichia coli. Science 301 (2003) 610-615
17. 2+-binding site. J. Biol. Chem. 274 (1999) 36928-36934
18. 2+ switches in the GABA transporter-1: differential effects on GABA uptake and currents. J. Biol. Chem. 276 (2001) 40476-40485
19. Norregaard L., et al. Evidence for distinct sodium-, dopamine-, and cocaine-dependent conformational changes in transmembrane segments 7 and 8 of the dopamine transporter. J. Biol. Chem. 278 (2003) 30587-30596
20. Mitchell S.M., et al. Structure and function of extracellular loop 4 of the serotonin transporter as revealed by cysteine-scanning mutagenesis. J. Biol. Chem. 279 (2004) 24089-24099
21. 2+ switch in the dopamine transporter: mutation of an intracellular tyrosine constitutively alters the conformational equilibrium of the transport cycle. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 1683-1688
22. Kilic F., and Rudnick G. Oligomerization of serotonin transporter and its functional consequences. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 3106-3111
23. Schmid J.A., et al. Oligomerization of the human serotonin transporter and of the rat GABA transporter 1 visualized by fluorescence resonance energy transfer microscopy in living cells. J. Biol. Chem. 276 (2001) 3805-3810
24. Sorkina T., et al. Oligomerization of dopamine transporters visualized in living cells by fluorescence resonance energy transfer microscopy. J. Biol. Chem. 278 (2003) 28274-28283
25. Hastrup H., et al. The human dopamine transporter forms a tetramer in the plasma membrane: cross-linking of a cysteine in the fourth transmembrane segment is sensitive to cocaine analogs. J. Biol. Chem. 278 (2003) 45045-45048
26. Farhan H., et al. Two discontinuous segments in the carboxyl terminus are required for membrane targeting of the rat gamma-aminobutyric acid transporter-1 (GAT1). J. Biol. Chem. 279 (2004) 28553-28563
27. Korkhov V.M., et al. Oligomerization of the γ-aminobutyric acid transporter-1 is driven by an interplay of polar and hydrophobic interactions in transmembrane helix II. J. Biol. Chem. 279 (2004) 55728-55736
28. Kobilka B.K., and Gether U. Use of fluorescence spectroscopy to study conformational changes in the β2-adrenoceptor. Methods Enzymol. 343 (2002) 170-182
29. Koch H.P., and Larsson H.P. Small-scale molecular motions accomplish glutamate uptake in human glutamate transporters. J. Neurosci. 25 (2005) 1730-1736
30. Seal R.P., and Amara S.G. Excitatory amino acid transporters: a family in flux. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 431-456
31. Ingram S.L., et al. Dopamine transporter-mediated conductances increase excitability of midbrain dopamine neurons. Nat. Neurosci. 5 (2002) 971-978
32. Trotti D., et al. Amyotrophic lateral sclerosis-linked glutamate transporter mutant has impaired glutamate clearance capacity. J. Biol. Chem. 276 (2001) 576-582
33. Hahn M.K., et al. A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters. J. Neurosci. 23 (2003) 4470-4478
34. Kilic F., et al. A human serotonin transporter mutation causes constitutive activation of transport activity. Mol. Pharmacol. 64 (2003) 440-446
35. Sutcliffe J.S., et al. Allelic heterogeneity at the serotonin transporter locus (SLC6A4) confers susceptibility to autism and rigid-compulsive behaviors. Am. J. Hum. Genet. 77 (2005) 265-279
36. Henry L.K., et al. Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants. J. Biol. Chem. 281 (2006) 2012-2023
37. Sanchez C., et al. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl.) 174 (2004) 163-176
38. Storustovu S., et al. R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. Br. J. Pharmacol. 142 (2004) 172-180
39. Wall S.C., et al. Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux. Mol. Pharmacol. 47 (1995) 544-550
40. Pifl C., and Singer E.A. Ion dependence of carrier-mediated release in dopamine or norepinephrine transporter-transfected cells questions the hypothesis of facilitated exchange diffusion. Mol. Pharmacol. 56 (1999) 1047-1054
41. Scholze P., et al. The role of zinc ions in reverse transport mediated by monoamine transporters. J. Biol. Chem. 277 (2002) 21505-21513
42. Sitte H.H., et al. Carrier-mediated release, transport rates, and charge transfer induced by amphetamine, tyramine, and dopamine in mammalian cells transfected with the human dopamine transporter. J. Neurochem. 71 (1998) 1289-1297
43. Kahlig K.M., et al. Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 3495-3500
44. Khoshbouei H., et al. N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol. 2 (2004) E78
45. Foster J.D., et al. Dopamine transporters are phosphorylated on N-terminal serines in rat striatum. J. Biol. Chem. 277 (2002) 25178-25186
46. Granas C., et al. N-terminal truncation of the dopamine transporter abolishes phorbol ester- and substance P receptor-stimulated phosphorylation without impairing transporter internalization. J. Biol. Chem. 278 (2003) 4990-5000
47. Johnson L.A., et al. Regulation of amphetamine-stimulated dopamine efflux by protein kinase Cβ. J. Biol. Chem. 280 (2005) 10914-10919
48. Desai R.I., et al. Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J. Neurosci. 25 (2005) 1889-1893
49. Ferrer J., and Javitch J.A. Cocaine alters the accessibility of endogenous cysteines in putative extracellular and extracellular loops of the human dopamine transporter. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 9238-9243
50. Reith M.E., et al. The uptake inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter. J. Biol. Chem. 276 (2001) 29012-29018
51. Katz J.L., et al. Effects of N-substituted analogues of benztropine: diminished cocaine-like effects in dopamine transporter ligands. J. Pharmacol. Exp. Ther. 309 (2004) 650-660
52. Braestrup C., et al. (R)-N-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]nipecotic acid binds with high affinity to the brain γ-aminobutyric acid uptake carrier. J. Neurochem. 54 (1990) 639-647
53. Schousboe A., et al. GABA transporters as drug targets for modulation of GABAergic activity. Biochem. Pharmacol. 68 (2004) 1557-1563
54. White H.S., et al. First demonstration of a functional role for central nervous system betaine/γ-aminobutyric acid transporter (mGAT2) based on synergistic anticonvulsant action among inhibitors of mGAT1 and mGAT2. J. Pharmacol. Exp. Ther. 312 (2005) 866-874
55. Schousboe A., et al. Role of astrocytic transport processes in glutamatergic and GABAergic neurotransmission. Neurochem. Int. 45 (2004) 521-527
56. Eulenburg V., et al. Glycine transporters: essential regulators of neurotransmission. Trends Biochem. Sci. 30 (2005) 325-333
57. Aragon C., and Lopez-Corcuera B. Structure, function and regulation of glycine neurotransporters. Eur. J. Pharmacol. 479 (2003) 249-262
58. Chen L., et al. Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J. Neurophysiol. 89 (2003) 691-703
59. Sepkuty J.P., et al. A neuronal glutamate transporter contributes to neurotransmitter GABA synthesis and epilepsy. J. Neurosci. 22 (2002) 6372-6379
60. Shigeri Y., et al. Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res. Brain Res. Rev. 45 (2004) 250-265
61. Rothstein J.D., et al. β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433 (2005) 73-77
62. 2+ inhibits glycine transport by glycine transporter subtype 1b. J. Biol. Chem. 279 (2004) 22983-22991
63. Cohen-Kfir E., et al. Zinc inhibition of γ-aminobutyric acid transporter 4 (GAT4) reveals a link between excitatory and inhibitory neurotransmission. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 6154-6159
64. Vandenberg R.J., et al. Molecular basis for differential inhibition of glutamate transporter subtypes by zinc ions. Mol. Pharmacol. 54 (1998) 189-196
65. Eshleman A.J., et al. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J. Pharmacol. Exp. Ther. 289 (1999) 877-885
66. Vallejo-Illarramendi A., et al. A novel alternative splicing form of excitatory amino acid transporter 1 is a negative regulator of glutamate uptake. J. Neurochem. 95 (2005) 341-348
67. Reye P., et al. Distribution of two splice variants of the glutamate transporter GLT-1 in rat brain and pituitary. Glia 38 (2002) 246-255
68. Guo H., et al. Human glioma cells and undifferentiated primary astrocytes that express aberrant EAAT2 mRNA inhibit normal EAAT2 protein expression and prevent cell death. Mol. Cell. Neurosci. 21 (2002) 546-560
69. Rozyczka J., and Engele J. Multiple 5′-splice variants of the rat glutamate transporter-1. Brain Res. Mol. Brain Res. 133 (2005) 157-161